

ABSTRACT OF THE DISCLOSURE

The present invention relates generally to programmed cell death and specifically to methods, compositions, and kits for preserving or enhancing antigenicity of markers associated with disease by utilizing inhibitors of apoptosis including interleukin-1 β -converting enzyme (ICE)/CED-3 family inhibitors.

D:\263110_1.DOC